-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
If You Like EPS Growth Then Check Out Porton Pharma Solutions (SZSE:300363) Before It's Too Late
If You Like EPS Growth Then Check Out Porton Pharma Solutions (SZSE:300363) Before It's Too Late
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks with a good story, even if those businesses lose money. And in their study titled Who Falls Prey to the Wolf of Wall Street?' Leuz et. al. found that it is 'quite common' for investors to lose money by buying into 'pump and dump' schemes.
So if you're like me, you might be more interested in profitable, growing companies, like Porton Pharma Solutions (SZSE:300363). While profit is not necessarily a social good, it's easy to admire a business that can consistently produce it. Loss-making companies are always racing against time to reach financial sustainability, but time is often a friend of the profitable company, especially if it is growing.
Check out our latest analysis for Porton Pharma Solutions
Porton Pharma Solutions's Improving Profits
In the last three years Porton Pharma Solutions's earnings per share took off like a rocket; fast, and from a low base. So the actual rate of growth doesn't tell us much. As a result, I'll zoom in on growth over the last year, instead. Like the last firework on New Year's Eve accelerating into the sky, Porton Pharma Solutions's EPS shot from CN¥0.68 to CN¥1.50, over the last year. Year on year growth of 121% is certainly a sight to behold. The best case scenario? That the business has hit a true inflection point.
I like to see top-line growth as an indication that growth is sustainable, and I look for a high earnings before interest and taxation (EBIT) margin to point to a competitive moat (though some companies with low margins also have moats). The good news is that Porton Pharma Solutions is growing revenues, and EBIT margins improved by 5.1 percentage points to 23%, over the last year. Ticking those two boxes is a good sign of growth, in my book.
The chart below shows how the company's bottom and top lines have progressed over time. To see the actual numbers, click on the chart.
SZSE:300363 Earnings and Revenue History May 16th 2022Of course the knack is to find stocks that have their best days in the future, not in the past. You could base your opinion on past performance, of course, but you may also want to check this interactive graph of professional analyst EPS forecasts for Porton Pharma Solutions.
Are Porton Pharma Solutions Insiders Aligned With All Shareholders?
We would not expect to see insiders owning a large percentage of a CN¥41b company like Porton Pharma Solutions. But we are reassured by the fact they have invested in the company. Indeed, they have a glittering mountain of wealth invested in it, currently valued at CN¥11b. That equates to 27% of the company, making insiders powerful and aligned with other shareholders. Very encouraging.
Is Porton Pharma Solutions Worth Keeping An Eye On?
Porton Pharma Solutions's earnings per share growth have been levitating higher, like a mountain goat scaling the Alps. That EPS growth certainly has my attention, and the large insider ownership only serves to further stoke my interest. The hope is, of course, that the strong growth marks a fundamental improvement in the business economics. So to my mind Porton Pharma Solutions is worth putting on your watchlist; after all, shareholders do well when the market underestimates fast growing companies. Still, you should learn about the 2 warning signs we've spotted with Porton Pharma Solutions (including 1 which is a bit concerning) .
Of course, you can do well (sometimes) buying stocks that are not growing earnings and do not have insiders buying shares. But as a growth investor I always like to check out companies that do have those features. You can access a free list of them here.
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks with a good story, even if those businesses lose money. And in their study titled Who Falls Prey to the Wolf of Wall Street?' Leuz et. al. found that it is 'quite common' for investors to lose money by buying into 'pump and dump' schemes.
很自然,许多投资者,尤其是那些刚接触这个游戏的人,更喜欢购买有好故事的“性感”股票,即使这些公司亏损。在他们题为谁会成为华尔街之狼的牺牲品?Leuz et.艾尔他们发现,投资者买入“哄抬和抛售”方案而蒙受损失是“相当常见”的。
So if you're like me, you might be more interested in profitable, growing companies, like Porton Pharma Solutions (SZSE:300363). While profit is not necessarily a social good, it's easy to admire a business that can consistently produce it. Loss-making companies are always racing against time to reach financial sustainability, but time is often a friend of the profitable company, especially if it is growing.
因此,如果你和我一样,你可能会对盈利的、成长型的公司更感兴趣,比如波顿制药解决方案(SZSE:300363)。虽然利润不一定是一种社会公益,但人们很容易钦佩一家能够持续创造利润的企业。亏损的公司总是在与时间赛跑,以实现财务上的可持续性,但时间往往是盈利公司的朋友,特别是如果它还在增长的话。
Check out our latest analysis for Porton Pharma Solutions
查看我们对Porton Pharma Solutions的最新分析
Porton Pharma Solutions's Improving Profits
波顿制药解决方案公司不断提高的利润
In the last three years Porton Pharma Solutions's earnings per share took off like a rocket; fast, and from a low base. So the actual rate of growth doesn't tell us much. As a result, I'll zoom in on growth over the last year, instead. Like the last firework on New Year's Eve accelerating into the sky, Porton Pharma Solutions's EPS shot from CN¥0.68 to CN¥1.50, over the last year. Year on year growth of 121% is certainly a sight to behold. The best case scenario? That the business has hit a true inflection point.
在过去的三年里,Porton Pharma Solutions的每股收益像火箭一样快速增长,而且基数很低。因此,实际的增长率并不能告诉我们太多。因此,我将把重点放在去年的增长上。就像除夕夜的最后一场烟花一样,波顿医药解决方案的每股收益在过去一年里从0.68元飙升至1.50元。121%的同比增长当然是一个令人惊叹的景象。最好的情况是什么?业务已经达到了一个真正的转折点。
I like to see top-line growth as an indication that growth is sustainable, and I look for a high earnings before interest and taxation (EBIT) margin to point to a competitive moat (though some companies with low margins also have moats). The good news is that Porton Pharma Solutions is growing revenues, and EBIT margins improved by 5.1 percentage points to 23%, over the last year. Ticking those two boxes is a good sign of growth, in my book.
我喜欢将营收增长视为增长是可持续的迹象,我希望息税前利润(EBIT)达到较高的利润率,以表明这是一条具有竞争力的护城河(尽管一些利润率较低的公司也有护城河)。好消息是,Porton Pharma Solutions的收入正在增长,息税前利润比去年提高了5.1个百分点,达到23%。在我看来,勾选这两个方框是增长的一个好迹象。
The chart below shows how the company's bottom and top lines have progressed over time. To see the actual numbers, click on the chart.
下面的图表显示了该公司的利润和收入是如何随着时间的推移而变化的。要查看实际数字,请点击图表。
Of course the knack is to find stocks that have their best days in the future, not in the past. You could base your opinion on past performance, of course, but you may also want to check this interactive graph of professional analyst EPS forecasts for Porton Pharma Solutions.
当然,诀窍是找到未来最好的股票,而不是过去的股票。当然,你可以根据过去的表现来发表你的观点,但你也可能想要查看这张专业分析师对Porton Pharma Solutions的每股收益预测的互动图表。
Are Porton Pharma Solutions Insiders Aligned With All Shareholders?
波顿制药解决方案的内部人员是否与所有股东保持一致?
We would not expect to see insiders owning a large percentage of a CN¥41b company like Porton Pharma Solutions. But we are reassured by the fact they have invested in the company. Indeed, they have a glittering mountain of wealth invested in it, currently valued at CN¥11b. That equates to 27% of the company, making insiders powerful and aligned with other shareholders. Very encouraging.
我们不希望看到内部人士拥有像Porton Pharma Solutions这样一家净资产410亿元的公司的很大比例。但让我们放心的是,他们对该公司进行了投资。事实上,他们有一座闪闪发光的财富山投资于它,目前价值110亿元人民币。这相当于公司27%的股份,这让内部人士变得强大,并与其他股东结盟。非常鼓舞人心。
Is Porton Pharma Solutions Worth Keeping An Eye On?
波顿制药解决方案值得关注吗?
Porton Pharma Solutions's earnings per share growth have been levitating higher, like a mountain goat scaling the Alps. That EPS growth certainly has my attention, and the large insider ownership only serves to further stoke my interest. The hope is, of course, that the strong growth marks a fundamental improvement in the business economics. So to my mind Porton Pharma Solutions is worth putting on your watchlist; after all, shareholders do well when the market underestimates fast growing companies. Still, you should learn about the 2 warning signs we've spotted with Porton Pharma Solutions (including 1 which is a bit concerning) .
Porton Pharma Solutions的每股收益增长一直在不断攀升,就像一只爬上阿尔卑斯山的山羊。每股收益的增长当然引起了我的注意,而大量的内部人士持股只会进一步激起我的兴趣。当然,人们希望,强劲的增长标志着商业经济学的根本改善。因此,在我看来,Porton Pharma Solutions值得列入你的观察名单;毕竟,当市场低估快速增长的公司时,股东表现良好。不过,您应该了解一下2个警告标志我们已经发现了Porton Pharma Solutions(包括1,这有点令人担忧)。
Of course, you can do well (sometimes) buying stocks that are not growing earnings and do not have insiders buying shares. But as a growth investor I always like to check out companies that do have those features. You can access a free list of them here.
当然,你可以(有时)买入这样的股票不是不断增长的收入和不要有内部人士购买股票。但作为成长型投资者,我总是喜欢看那些做拥有这些功能。你可以在这里访问它们的免费列表。
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
请注意,本文中讨论的内幕交易指的是相关司法管辖区内的应报告交易。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧